CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,542 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03649646
NCT03649646N/ACompleted

A Multi-center, Open, Longitudinal, Observational Study to Assess the Treatment Trend and the Proportion of Target BP Attainment in Patients Whose Antihypertensive Regimens Are Changed to ARB-based Therapy

Boryung Pharmaceutical Co., Ltd·observational·Posted Aug 28, 2018·Updated Jan 12, 2021

In Brief

An observational study for Essential Hypertension. Completed, enrolled 4,542 participants across 1 site.

Detailed Summary

The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in hypertension treatment. However, studies in Koreans must be preceded before applying such new overseas guidelines; thus, this study has been designed to establish clinical materials reflecting treatment setting in Korea. In this study, patients with uncontrolled hypertension whose antihypertensive regimens are changed to ARB-based therapy (ARB monotherapy or ARB-containing combination therapy) will be followed to assess the treatment trend, treatment effect, and risk of cardiovascular disease.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 28, 2018
Enrollment StartJul 3, 2018
Primary CompletionOct 29, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.8 years ago